Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer
HeadHER1/EGFR is known to play a pivotal role in tumorigenesis and is overexpressed in up to 80% of NSCLCs. The study of an Expanded Access Clinical Program of Erlotinib in NSCLC is a phase IV openlabel, non-randomized, multicenter trial in patients with advanced (inoperable stage IIIb/IV) NSCLC wh...
Main Authors: | Bakir Mehić, Mirko Stanetić, Ljuljeta Tinjić, Vlatka Smoljanović |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2008-11-01
|
Series: | Biomolecules & Biomedicine |
Subjects: | |
Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/2905 |
Similar Items
-
Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report
by: Magdalena Żychowska, et al.
Published: (2016-10-01) -
Case study: Participation of Bosnia and Herzegovina in the EU common security and defense policy: Possibilities of regional cooperation
by: Garić Nenad, et al.
Published: (2015-01-01) -
Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022-07-01) -
From the Territorial Defence Forces to the Army of the Republic – The formation of the Armed Forces in light of the Decisions of the Presidency of the Republic of Bosnia and Herzegovina
by: Mesud Šadinlija
Published: (2023-06-01) -
„Problematično” osmansko naslijeđe i opći problemi recepcije, klasifikacije i periodizacije starije bošnjačke književnosti na osmanskom jeziku
by: Adnan Kadrić
Published: (2015-08-01)